Please login to the form below

Not currently logged in
Email:
Password:

J&J and LDC to join forces on unmet medical needs

Collaboration will aim to find and accelerate new potential treatments

Johnson & Johnson headquarters 

Johnson & Johnson and the Lead Discovery Center (LDC) have collaborated to support drug candidates for highly unmet medical needs.

The two-year collaboration will aim to identify and accelerate potential candidates for the treatment and prevention of diseases that are shown to require further research and attention.

The LDC and J&J's London Innovation Centre will look into ongoing translational research opportunities sourced from the former's academic network, including institutes from the Max Planck Society, the Helmholtz Association and universities.

Dr Bert Klebl, CEO of the LDC, commented: “Through our academic network, we have access to a broad range of exciting molecular targets, pathobiological mechanisms and new therapeutic approaches which are the basis for project proposals with a high innovation potential for drug discovery.

“Together with Johnson & Johnson Innovation, we will now be able to offer a solution for more of our academic partners to translate their innovative findings into benefit for patients.”

J&J will review the candidates with the aim to discovery drugs that can make an impact on patients. For each project selected, the partners with negotiate a collaboration agreement for its joint development at the LDC.

Article by
Kirstie Pickering

12th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics